Skip to main content
Top
Published in: Clinical Rheumatology 6/2007

01-06-2007 | Brief Report

Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease

Authors: Albert Selva-O’Callaghan, Eva Balada, Silvia Serrano-Acedo, Carmen Pilar Simeon Aznar, Josep Ordi-Ros

Published in: Clinical Rheumatology | Issue 6/2007

Login to get access

Abstract

Pulmonary arterial hypertension is a recognized clinical component of systemic autoimmune diseases, especially systemic sclerosis. Mutations in the bone morphogenetic protein receptor 2 gene reported in sporadic and familial primary pulmonary arterial hypertension have failed to be detected in patients with either scleroderma spectrum disease or underlying connective tissue diseases. Activin receptor-like kinase 1 (ALK-1) gene has recently been linked to the pathogenesis of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia, which has some resemblance with the CREST syndrome. The presence of mutations in the ALK-1 gene in ten patients with underlying connective tissue diseases was investigated.
Literature
2.
go back to reference Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE et al (1997) The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 61:60–67PubMed Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE et al (1997) The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 61:60–67PubMed
3.
go back to reference Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I et al (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345:325–334PubMedCrossRef Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I et al (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345:325–334PubMedCrossRef
4.
go back to reference Vollmann J, Winau R (1996) Informed consent in human experimentation before the Nuremberg code. BMJ 313:1445–1449PubMed Vollmann J, Winau R (1996) Informed consent in human experimentation before the Nuremberg code. BMJ 313:1445–1449PubMed
5.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
6.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska SA, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska SA, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
7.
go back to reference Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK et al (2000) Activin receptor-like kinase 1 modulates transforming growth factor-β 1 signaling in the regulation of the angiogenesis. Proc Natl Acad Sci USA 97:2626–2631PubMedCrossRef Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK et al (2000) Activin receptor-like kinase 1 modulates transforming growth factor-β 1 signaling in the regulation of the angiogenesis. Proc Natl Acad Sci USA 97:2626–2631PubMedCrossRef
9.
go back to reference Tew MB, Arnett FC, Reveille JD, Tan FK (2002) Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 46:2829–2830PubMedCrossRef Tew MB, Arnett FC, Reveille JD, Tan FK (2002) Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 46:2829–2830PubMedCrossRef
10.
go back to reference Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J (2002) Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 29:2379–2381PubMed Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J (2002) Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 29:2379–2381PubMed
11.
go back to reference Satoh T, Kimura K, Okano Y, Hirakata M, Kawakami Y, Kuwana M (2005) Lack of circulating autoantibodies to bone morphogenetic protein receptor II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension. Rheumatology 44:192–196PubMedCrossRef Satoh T, Kimura K, Okano Y, Hirakata M, Kawakami Y, Kuwana M (2005) Lack of circulating autoantibodies to bone morphogenetic protein receptor II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension. Rheumatology 44:192–196PubMedCrossRef
Metadata
Title
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease
Authors
Albert Selva-O’Callaghan
Eva Balada
Silvia Serrano-Acedo
Carmen Pilar Simeon Aznar
Josep Ordi-Ros
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0388-x

Other articles of this Issue 6/2007

Clinical Rheumatology 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine